Kiromic Biopharma Inc 's ROA from the fourth quarter of 2024 to the fourth quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kiromic Biopharma Inc 's ROA in the fourth quarter of 2024?
Kiromic Biopharma Inc recorded a cumulative net loss of $-27 million during 12 months ending in the fourth quarter of 2024, resulting in a negative return on assets (ROA) of -248.04%.

However, within the Healthcare sector 1035 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2024 from 4878 to 5528.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter
Y / Y Total Assets Change	-26.37 %	-28.69 %	-2.43 %	-6.72 %	-3.03 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-27	-25	-22	-22	-21
Return On Assets (TTM)	-248.04 %	-216.2 %	-173.06 %	-171.52 %	-162.05 %
KRBP's Total Ranking	# 5528	# 4878	# 4853	# 4907	# 5641
Total Assets (TTM) in million	9	10	12	12	12
Seq. Total Assets Change	-15.81 %	-18.57 %	2.01 %	5.28 %	-18.47 %
Seq. Net Income Change	-	-	-	-	-

KRBP's 5 Years Annual ROA >> Back to KRBP Management Effectiveness >> Compare KRBP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 165
Sector	# 1036
Overall	# 5441

Return On Assets Statistics
High	Average	Low
-108.45 %	-181.04 %	-299.09 %
(Sep 30 2021)		(Mar 31 2021)

News about Kiromic Biopharma Inc Return on Assets ROA

In a landscape where innovation competes fiercely with financial stability, Kiromic BioPharma, Inc. (OTCQB ...

Harnessing Innovation: Kiromic BioPharma’s Deltacel Trial Shows Promise Amid Financial Struggles In a landscape where innovation competes fiercely with financial stability, Kiromic BioPharma, Inc. (OTCQB: KRBP) is making waves with its Deltacel-01 Phase 1 clinical trial. The study is evaluating Deltacel (KB-GDT-01), a pioneering allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy aimed at patients battling stage 4 metastatic non-small cell lung cancer (NSCLC) who have not found success with standard treatments. Recent reports indicate favorable ongoing efficacy results from follow-up visits for two participants in the trial, referred to as Patient 4 and Patient 6.These promising findings come at a critical time. The six-month follow-up has sparked hope not only within the scientific community but also among the families affected by a disease that typically lays waste to traditional therapeutic avenues. With the pall of financial difficulties looming overhead a cumulative net loss of $22 million over the past year and a staggering negative return on assets (ROA) of -173.06% the pressing need for clinical success has never been more acute for Kiromic and its stakeholders. It is worth noting that, within the Healthcare sector, 590 other companies currently boast a higher ROA, underscoring the challenging environment Kiromic navigates as it strives to bring novel therapies to market.

Hope for Lung Cancer Patients Kiromic BioPharmas Deltacel-01 Shows Promise in Latest Clinical Trial Resul...

In an exciting development for oncology and immunotherapy, Kiromic BioPharma, Inc. (OTCQB: KRBP) announced favorable updates regarding its Deltacel-01 clinical trial, which is assessing the safety and efficacy of Deltacel (KB-GDT-01). This innovative allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy targets patients suffering from stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to conventional treatment methods.The latest update marks a significant milestone in the Deltacel-01 trial, where the first patient treated has now reached a 10-month follow-up period. Results from this visit have demonstrated not only a strong safety profile but also favorable ongoing efficacy, indicating that Deltacel may offer a new ray of hope for patients facing limited treatment options. As NSCLC remains one of the leading causes of cancer-related deaths worldwide, these developments can be crucial in changing the treatment landscape for patients battling late-stage disease.

Financial Statements
Kiromic Biopharma Inc 's Assets	$ 9 million	KRBP's Balance sheet
Kiromic Biopharma Inc 's Income	$ -6 million	Quarterly KRBP's Income Statement
KRBP's Income by Division		See KRBP's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-26.37 %	-3.03 %	-61.06 %	139.52 %	-
Total Assets in million	9	12	12	31	13
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-27	-21	-35	-26	-19
Annual Return On Assets	-314.78 %	-180.52 %	-290.21 %	-83.27 %	-149.65 %

KRBP's 5 Years Annual ROA >> Back to KRBP Management Effectiveness >> Compare KRBP ROA to its Competitors

More Return On Assets Ratios
KRBP's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KRBP's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KRBP's Competitors
Subscribers only: Roa for Kiromic Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for KRBP's Customers

You may also want to know
KRBP's Roi	KRBP's Inventory Turnover Ratio	KRBP's Growth Rates	KRBP's Dividend Comparisons
	KRBP's Profitability Ratios	KRBP's Asset Turnover Ratio	KRBP's Dividend Growth
KRBP's Roe	KRBP's Valuation Ratios	KRBP's Financial Strength Ratios	KRBP's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.